Clinical Trial Search

Primary: Successful Engraftment Using Cyclophosphamide Post-Transplant — 1.00; 0.93 Cumulative Probability of Engraftment

Primary: Percent Vital Bone Formation, — 26.8; 39.3 percentage of vital bone

Primary: Arm 1: Objective Response Rate (ORR) — 18.0 percentage of participants — p=0.0148

Primary: Patient Adherence to Use a Walking Platform — 26 Participants

Primary: Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs — 4.37; 4.27 Scores on a scale

Primary: Median Number of Frozen Sections (or Parathyroid Aspirate) Sent for Analysis — 0; 0 frozen aspirate samples

Primary: Virtual Environment TBI System (VETS) Assessment of Static Posturography — 11; 13.0; 48.4; 19.1 Square Centimeters

Primary: Change in Hb Levels as Mean of Visits Between Day 126 and Day 168 Compared to Baseline Tested for Non-inferiority — 2.01 g/dL — p=<0.0001

Primary: Maximally Tolerated Dose/Fractionation of Hypofractionated Radiation Therapy — 0 Participants

Primary: Visual Analogue Scale (VAS) Scores of the Tooth Sensitivity Questionnaire Collected Through the Study — 33.8; 41.6; 36.9; 31.1 millimeter

Primary: AUC0-tlast of Midazolam — 34331.8; 28619.6 h*pg/ml

Primary: Percentage of Participants With Acute Procedural Success (APS) — 93.9 percentage of participants

Primary: Effectiveness Measure: Tumor Disease Control Rate Reaches the Objective Performance Criteria (80%) — 42 Participants

Primary: PROMIS Physical and Mental Scores — 50.46; 50.26; 56.51; 60.21 score on a scale — p=0.91

Primary: Energy (Kilocalorie or kcal) Intake — 2128.8; 2120.0 kcal/day